Science

May 5, 2025, 14:17

Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib

Oscar Tahuahua, Medical Oncology fellow at the National Cancer Institute of Mexico , shared a post on X:

“Real-world data, 1323 pts w/EGFRm NSCLC received 1L osimertinib: mOS 28.6 mo (< FLAURA trial)

18% reached 5-y survival; 29% died before 2L, 4% had no further therapy and 19% remained on 1L

Findings support need for optimized 1L combos in high-risk pts.”

Title: Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States

Authors: Joshua K. Sabaria, Helena A. Yub, Parthiv J. Mahadeviac, Yanfang Liud , Levon Demirdjiane, Yen Hua Chend, Xiayi Wangf, Antonio Passaro.

You can read the Full Article on Journal of Thoracic Oncology.

Non-Small Cell Lung Cancer

More posts featuring Oscar Tahuahua.

Antonio Passaro cancer Helena A. Yub Joshua K. Sabaria Levon Demirdjiane Lung cancer NSCLC OncoDaily Oncology Oscar Tahuahua osimertinib Parthiv J. Mahadeviac Xiayi Wangf Yanfang Liud Yen Hua Chend

Does Plastic Cause Cancer? Myths and Facts

TOPGEAR trial at ESTRO 2025: Preoperative Chemoradiotherapy for Resectable Gastric Cancer

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Bianca Balti: The Supermodel’s Brave Battle with Ovarian Cancer

NCD Frontlines with Saunthari Somasundaram | A New OncoDaily Podcast – Coming Soon